Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease

Steven Douglas Maynard,1,2 Jeff Gelblum31Union Associated Physicians Clinic, 2Indiana University School of Medicine, Terre Haute, IN, 3Mt Sinai Medical Center of Miami, Aventura Hospital, Aventura, FL, USAAbstract: Under normal conditions, the adult human brain is fueled primarily by glucose. A prom...

Full description

Bibliographic Details
Main Authors: Maynard SD, Gelblum J
Format: Article
Language:English
Published: Dove Medical Press 2013-10-01
Series:Neuropsychiatric Disease and Treatment
Online Access:http://www.dovepress.com/retrospective-case-studies-of-the-efficacy-of-caprylic-triglyceride-in-a14766
id doaj-402888dbf20b4af4bd076c348d2c6989
record_format Article
spelling doaj-402888dbf20b4af4bd076c348d2c69892020-11-24T22:21:33ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212013-10-012013default16291635Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's diseaseMaynard SDGelblum JSteven Douglas Maynard,1,2 Jeff Gelblum31Union Associated Physicians Clinic, 2Indiana University School of Medicine, Terre Haute, IN, 3Mt Sinai Medical Center of Miami, Aventura Hospital, Aventura, FL, USAAbstract: Under normal conditions, the adult human brain is fueled primarily by glucose. A prominent feature of Alzheimer's disease (AD) is region-specific decreases in cerebral glucose metabolism. Ketone bodies are a group of compounds produced from fat stores during periods of low glucose availability that can provide an alternative to glucose for brain metabolism. Consumption of sufficient quantities of caprylic triglyceride (CT) increases plasma concentrations of ketone bodies and may be beneficial in conditions of compromised glucose metabolism, such as AD. The present study describes the use of CT in mild-to-moderate AD in routine clinical practice. Case records from eight patients with extensive monitoring of cognitive function using the Mini-Mental State Examination (MMSE) and who had received CT for ≥6 months were reviewed. All were outpatients aged ≥50 years, cared for in standard practice, had a diagnosis of probable AD of mild-to-moderate severity (MMSE 14–24), and had received CT for at least 6 months in addition to other approved pharmacotherapy for AD. Response to CT administration as measured by MMSE scores varied by patient. However, the rate of decline in MMSE scores appeared slower than previously published reports for patients treated with pharmacotherapy alone. Profiling of individual patients may provide insight regarding those most likely to benefit from addition of CT to currently approved AD pharmacotherapy.Keywords: ketosis, cognition, Alzheimer's disease, metabolism, glucosehttp://www.dovepress.com/retrospective-case-studies-of-the-efficacy-of-caprylic-triglyceride-in-a14766
collection DOAJ
language English
format Article
sources DOAJ
author Maynard SD
Gelblum J
spellingShingle Maynard SD
Gelblum J
Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
Neuropsychiatric Disease and Treatment
author_facet Maynard SD
Gelblum J
author_sort Maynard SD
title Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
title_short Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
title_full Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
title_fullStr Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
title_full_unstemmed Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease
title_sort retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate alzheimer's disease
publisher Dove Medical Press
series Neuropsychiatric Disease and Treatment
issn 1176-6328
1178-2021
publishDate 2013-10-01
description Steven Douglas Maynard,1,2 Jeff Gelblum31Union Associated Physicians Clinic, 2Indiana University School of Medicine, Terre Haute, IN, 3Mt Sinai Medical Center of Miami, Aventura Hospital, Aventura, FL, USAAbstract: Under normal conditions, the adult human brain is fueled primarily by glucose. A prominent feature of Alzheimer's disease (AD) is region-specific decreases in cerebral glucose metabolism. Ketone bodies are a group of compounds produced from fat stores during periods of low glucose availability that can provide an alternative to glucose for brain metabolism. Consumption of sufficient quantities of caprylic triglyceride (CT) increases plasma concentrations of ketone bodies and may be beneficial in conditions of compromised glucose metabolism, such as AD. The present study describes the use of CT in mild-to-moderate AD in routine clinical practice. Case records from eight patients with extensive monitoring of cognitive function using the Mini-Mental State Examination (MMSE) and who had received CT for ≥6 months were reviewed. All were outpatients aged ≥50 years, cared for in standard practice, had a diagnosis of probable AD of mild-to-moderate severity (MMSE 14–24), and had received CT for at least 6 months in addition to other approved pharmacotherapy for AD. Response to CT administration as measured by MMSE scores varied by patient. However, the rate of decline in MMSE scores appeared slower than previously published reports for patients treated with pharmacotherapy alone. Profiling of individual patients may provide insight regarding those most likely to benefit from addition of CT to currently approved AD pharmacotherapy.Keywords: ketosis, cognition, Alzheimer's disease, metabolism, glucose
url http://www.dovepress.com/retrospective-case-studies-of-the-efficacy-of-caprylic-triglyceride-in-a14766
work_keys_str_mv AT maynardsd retrospectivecasestudiesoftheefficacyofcaprylictriglycerideinmildtomoderatealzheimer39sdisease
AT gelblumj retrospectivecasestudiesoftheefficacyofcaprylictriglycerideinmildtomoderatealzheimer39sdisease
_version_ 1725770598724927488